

**Research Consensus Panel for the Development of a Research Agenda in  
Renal Ablation  
Room: Concorde A  
Hyatt Dulles, Northern Virginia  
Monday, April 26, 2010  
8:30am – 3:00pm  
(8:00-8:30 a.m. Continental Breakfast)**

**Meeting Agenda**

OBJECTIVE: To define a prioritized research agenda for Renal Ablation, including topics amenable to basic science/technology research, pilot clinical research, and multi-center clinical trials. This process will involve several steps:

1. **PANELISTS' RESEARCH PRESENTATIONS AND DISCUSSION:** Key aspects of the already-existing knowledge base for each research domain will be summarized by a panel member. A moderated discussion will be held to address the following questions for each domain:

1. What are the most important clinical questions that could realistically be answered now through pivotal multi-institutional clinical trials or registries?
2. What are the most promising future directions that merit pre-clinical or early clinical exploration in the field of Renal Ablation?
3. What critical alliances must be developed to advance the prioritized research, and how can SIR Foundation best support these initiatives?

2. **PRIORITIZATION:** Based upon the discussion, a summary list of potential research studies will be created. The panelists will rank the research projects in order of priority. The results will be compiled into a final rank list.

3. **PROTOCOL DEVELOPMENT:** The top-ranked research priority will be examined by the panel. A basic framework research protocol designed to address this question will be developed, with a strong focus on determining how to study the outcomes that are clinically meaningful.

Time Slot	Topic	Speaker
8:30-8:55 a.m.	Introductions. Explanation of the RCP Proceedings followed by a Renal Ablation Introduction Presentation	Stephen Kee, MD, & Deb Gervais, MD
8:55-9:05 a.m.	Epidemiology/Risk Factors/Natural History of RCC	Steve Raman, MD
9:05-9:15 a.m.	Diagnosis/Staging/Current Management of RCC	Raymond Leveillee, MD
9:15-9:25 a.m.	Nephron Sparing Surgery for RCC; (Safety & Efficacy)	Jeffrey Cadeddu MD
9:25-9:35 a.m.	Current Status of Metastectomy for RCC	Peter Littrup, MD
9:35-9:45a.m.	Systemic therapies for metastatic renal cell carcinoma	Hans Hammers, MD, PhD
9:45-9:55a.m.	Current Evidence on Perc.Ablation for RCC (Safety & Efficacy)	Thomas Atwell, MD

9:55-10:05 a.m.	Overview of RFA vs Cryo vs Microwave; Re: RCC	Ron Zagoria, MD, FACR
10:05-10:15 a.m.	Current Standards for Post-Treatment Follow-up	Kamran Ahrar, MD
10:15-10:25 a.m.	Cryoimmunotherapy Review for RCC	Ron Rodriguez, MD, PhD
10:25-10:35 a.m.	Creating a Registry	Jeremy Durack, MD, MS
10:35-10:50 a.m.	BREAK (15 minutes)	All
10:50 a.m.- 12 noon	<p>Panel Discussion &amp; Research Priority Topic Suggestions. (Priorities are typed for viewing on the screen and numbered as they are stated.)</p> <ul style="list-style-type: none"> <li>➤ TWO rounds around the panel table. <ol style="list-style-type: none"> <li>1. Round 1- Panel discussion. Each panelist has the opportunity to address the questions listed on page one of the agenda under Panel Discussion.</li> <li>2. Round 2- Each panelist suggests 1 or 2 clinical priorities and 1 basic science priority (optional: 1 organizational priority)</li> </ol> </li> <li>➤ Audience participants have the opportunity to suggest research priority topics (1 or 2 clinical, 1 basic science and 1 organizational).</li> </ul>	(Note: If there are registry topics these will be listed in a separate list.)
12:00-12:20 p.m.	Panel reviews the listed priorities and makes an effort to further consolidate/combine priorities into a list of 10 to 15 priorities. Panel agrees to any combinations that are made.	(Note: If there is a list of registry topics these will be consolidated also.)
12:20-12:30 p.m.	<p>Panelists vote on the priority topics.</p> <ul style="list-style-type: none"> <li>➤ Voting sheet has numbers that correspond to the research priority topic number listed on the screen.</li> </ul> <p>Next to each number on the voting sheet, write a number 1-5 identifying the rank of the priority. (1 is the highest rank and 5 is the lowest rank, rank numbers are used more than once.) (See the Prioritization Guidelines).</p>	(Note: If there is a list of registry research priority topics, there will be a separate voting sheet.)
12:30-1:15 p.m.	Lunch (Drs. Georgiades & Kee will collect votes, tally them, and will list the priorities to be viewed by the panel and audience on the screen.)	
1:15-2:00 p.m.	1 or 2 priorities are identified	(Note: Refer to the RCP Meeting Methodology for resolving ties.)

2:00-3:00 p.m.	<ul style="list-style-type: none"> <li>➤ Panel will suggest which panelist(s) will apply for the Funding Source Development Grant (June 28<sup>th</sup> deadline), which funds the development of a protocol for a clinical research trial on one of the top RCP priorities.</li> <li>➤ For the priority topic(s) : <ul style="list-style-type: none"> <li>▪ The protocol development is discussed as time allows answering questions such as: <ol style="list-style-type: none"> <li>1. What is the public health significance of the study?</li> <li>2. What would be the study's primary and secondary aims?</li> <li>3. What would be the study design?</li> <li>4. What would be the primary and secondary outcome measures?</li> <li>5. What would be the inclusion, exclusion criteria for participation in the study? What would be the study's structure?</li> </ol> </li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>➤ For more information on the Funding Source Development Grant application go to : <ol style="list-style-type: none"> <li>1. <a href="http://www.sirfoundation.org/grants-awards">http://www.sirfoundation.org/grants-awards</a></li> <li>2. And/or contact <a href="mailto:kmercure@sirweb.org">kmercure@sirweb.org</a></li> </ol> </li> </ul>
3:00 p.m.	Summary and meeting conclusion	Christos Georgiades, MD, PhD/ Stephen Kee, MD

Other panel members that will participate but will not be presenting include: Constantine Frangakis, PhD (Biostatistics), Max Meng, MD (Urologist), and Stephen Solomon, MD (IR)